RxDoctor Payments Data

Aditi Singh, MD

Hematology & Oncology · Philadelphia, PANPI 1093072134

Payments from drug & device makers

$95,190in general payments, 2019–2025

Across 12 payments — averaging $7932.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$92K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Beigene USA, Inc.$52
  • Novocure Inc.$25

What the payments were for

  • Consulting fees$2,96097%
  • Food & beverage$773%

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$95,190 in reported general payments places this provider in the 75th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,456
Medicare patients
142
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate27$429,730
EliquisApixaban11$10,466
Ondansetron Hcl11$156

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →